The mutations of TGFBR2 and PCNT and the dysregulations of TGF-β and other pathways might accelerate the B cell transformation, which may serve as a blast crisis risk indicator of CML. The gene discussed is TGFBR2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.